“We’re happy to strengthen our mental property safety with the addition of those new US patents,” acknowledged Keith Warner, Chief Government Officer of NeuraLace Medical. “Together with our sturdy worldwide IP portfolio, these patents bolster and broaden the safety of our core Axon know-how, highlighted by way of transcutaneous magnetic stimulation versus invasive and/or pharmacological options. The corporate’s scientific outcomes up to now have been spectacular, and we look ahead to this momentum carrying ahead to the completion and publication of our formal scientific research.”
The corporate is within the means of increasing websites of its ongoing randomized scientific trial specializing in utility of Axon remedy to neuropathic ache broadly, whereas additionally initiating a big research specializing in peripheral diabetic neuropathy, recognizing that for hundreds of thousands of sufferers the medication utilized in first line remedy turn into ineffective or aren’t effectively tolerated, and different modalities of therapy are wanted.
About NeuraLace Medical
Privately held NeuraLace Medical, Inc., headquartered in San Diego, Calif., is dedicated to main the cost in non-invasive power ache administration and sustainable aid. Our mission to finish power ache impressed us to develop Axon Remedy, with the aim of being the primary non-invasive, non-addictive strategy to successfully deal with power nerve ache.
With its distinctive product portfolio, protected by property patents and patent functions, NeuraLace Medical is effectively positioned to determine a management place within the medical system market. For extra data, please go to www.neuralacemedical.com.
For extra data, please contact:
Chief Government Workplace
SOURCE Neuralace Medical, Inc.